RecruitingPhase 2NCT06416007
Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors
A Phase 2 Study of Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors
Sponsor
University of Cincinnati
Enrollment
37 participants
Start Date
Aug 2, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this research study is to determine if lattice radiation therapy (LRT) will provide better treatment for bulky (large) tumors than current standard of care radiotherapy.
Eligibility
Min Age: 18 Years
Inclusion Criteria9
- Solid tumor malignancy with a clinical indication for radiation
- Patients must have measurable disease
- Target lesion(s) which are amenable to lattice therapy plan
- When applicable, target lesion for radiation amenable to immobilization during delivery of radiotherapy
- Age ≥18 years.
- ECOG Performance status ≤2
- Life expectancy greater than 3 months
- Women of child-bearing potential and men must agree to avoid conception via abstinence (ideal) or a method of birth control (e.g., hormonal or barrier method of birth control) prior to study entry and for at least 30 days after completion of lattice therapy administration.
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria6
- Patients receiving cytotoxic chemotherapy or known radiosensitizing agents within 5 days before or after lattice therapy.
- Patients with hematologic malignancies including lymphoma and leukemia as well as primary or metastatic central nervous system (CNS) malignancies.
- Patients with a history of conditions which predispose them to increased radiation toxicity
- Patients with known contraindications to radiation therapy
- Patients with uncontrolled intercurrent illness
- Pregnant women
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
RADIATIONLattice therapy (LRT)
5 Fractions LRT
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06416007
Related Trials
Immunotherapy Treating GI Cancer
NCT036146501 location
Patient-Centered Assessment of Symptoms and Outcomes
NCT039526241 location
Tumor Related Epilepsy
NCT026393251 location
Evaluating Disparities in Precision Oncology
NCT060815171 location
Cancer-related Venous Thromboembolic Disease - Cohort Study
NCT063937641 location